Navigation Links
Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
Date:2/17/2011

DURHAM, N.C., Feb. 17, 2011 /PRNewswire/ --  Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial.  Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

The MiStent DES employs Micell's proprietary supercritical fluid technology which applies a precisely controlled absorbable polymer - active drug (sirolimus) matrix onto a cobalt-chromium stent.  The polymer dissolves and releases the drug into the surrounding tissue in a controlled manner, designed to optimize dosing of the drug throughout the affected artery.  In GLP pre-clinical trials, the drug completely elutes and the polymer is eliminated from the stent within 45 to 60 days in vivo, resulting in a bare-metal stent.

DESSOLVE II is a prospective, controlled, 2:1 unbalanced randomized, multi-center study of approximately 270 patients.  Patients will be enrolled at 26 clinical sites in Europe, New Zealand and Australia.  Candidates for the trial are patients with documented stable or unstable angina pectoris or ischemia.  The primary endpoint is superiority of MiStent DES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor® DES, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm long stent.

Along with secondary clinical endpoints such as major adverse c
'/>"/>

SOURCE Micell Technologies Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 McGraw-Hill Education Professional, ... the science, technical, and medical communities, has announced the ... off-line mobile application of the world-renowned medical education platform. ... AccessMedicine App , available for download onto all ... be able to gain access to valuable AccessMedicine ...
(Date:7/29/2014)... New York , July 29, 2014 ... by Transparency Market Research "Orthopedic Trauma Fixation Devices Market ... Analysis 2014 - 2020", the global orthopedic trauma fixation ... 2014 and is expected to grow at a CAGR ... estimated value of USD 9.3 billion in 2020. ...
(Date:7/29/2014)... , July 29, 2014  Instrumentation Laboratory (IL) today ... a new corporate logo. This is part of a comprehensive ... Founded in Boston, MA , in ... of companies since 1992.  Other companies in the group include ... and Systelab ( Barcelona, Spain ).  Like IL, ...
Breaking Medicine Technology:McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3
... , STAMFORD, Conn., Nov. 13 ... will be releasing a free trial version of its Zargis ... conference, taking place this November 15-17 in Orlando. Zargis is ... the companion hardware -- the 3M Littmann Electronic Stethoscope Model ...
... BERWYN, Pa., Nov. 13 /PRNewswire-FirstCall/ -- Encorium Group, ... multinational clinical research organization (CRO) conducting studies in over ... and biotechnology companies, today announced that it has appointed ... 7, 2009. Ms. Laitinen, age 43, will replace ...
Cached Medicine Technology:Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 2Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 3Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 2Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 3
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 Daily ... that the program was actually created by a popular ... too. He tried numerous treatments for this disorder, but ... found himself in the situation of having to look ... years of research. Dawson used this method, too, to ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
(Date:7/29/2014)... Angeles, CA (PRWEB) July 29, 2014 ... the website of Time Magazine titled “From Kim’s Butt ... Kim Kardashian’s butt is the celebrity feature ... and their features include Beyoncé’s butt, Jennifer Lawrence’s ... lips. This information is based on data collected by ...
(Date:7/29/2014)... 29, 2014 Tylenol lawsuits ( ... allegedly suffered serious liver injuries due to the ... in a multidistrict litigation underway in U.S. District ... reports. According to an Order dated July 23rd, ... to bellwether case and discovery issues. Among other ...
(Date:7/29/2014)... Avenidas is always looking for ... again, the non-profit agency is doing just that with the ... , This event gives seniors the opportunity to learn about ... will be a variety of fun activities, including a Tai ... and artists. In addition, there will be food tastings, courtesy ...
Breaking Medicine News(10 mins):Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2
... Total hip arthroplasty (THA), or hip replacement, is ... studies have only followed patients for up to ... December issue of Arthritis Care & Research ( ... eight years following hip replacement and found a ...
... obtained agreement with the United States, Food and Drug ... SP1049C for the treatment of metastatic adenocarcinoma of the ... upper gastrointestinal tract, ... clinical trial will compare SP1049C plus Best Supportive Care (BSC),versus BSC ...
... Flick, presents World AIDS Day Special ... SIRIUS Satellite Radio,Interview with Madonna and exclusive performances from Cyndi Lauper, Indigo ... Bell and others, NEW YORK, Nov. 28 SIRIUS Satellite Radio,(Nasdaq: ... --,Saturday, December 1 -- with an exclusive broadcast event on SIRIUS OutQ,109, ...
... Over the past few weeks,there has been a ... the meat industry and the USDA that permits ... failed to be "non-negative" for E.,coli O157:H7,( http://www.ehagroup.com/epidemiology/illnesses/e-coli-O157-H7.asp ... includes cooking to the thermal death,stage for all ...
... Breast cancer is a disease with a number ... have seen that these risks are often compounded by ... exactly, do social disadvantages, genetics, race and culture add ... women? , These are among the questions in ...
... of Americans still weigh much too much, study finds , , ... hasn,t increased much in recent years, but there are still ... study reports. , The study, based on 2005-06 data from ... , More than a third of American adults (about 72 ...
Cached Medicine News:Health News:Long-term improvement seen with hip replacement 2Health News:Supratek Pharma Inc. announced today that under the Special Protocol 2Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 2Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 3Health News:The USDA 'E. coli Loophole' in Ground Beef: Much Ado About Nothing 2Health News:The USDA 'E. coli Loophole' in Ground Beef: Much Ado About Nothing 3Health News:New perspectives on health disparities in breast cancer research 2Health News:New perspectives on health disparities in breast cancer research 3Health News:New perspectives on health disparities in breast cancer research 4Health News:New perspectives on health disparities in breast cancer research 5Health News:New perspectives on health disparities in breast cancer research 6Health News:New perspectives on health disparities in breast cancer research 7Health News:New perspectives on health disparities in breast cancer research 8Health News:Obesity Rates Leveling Off Among U.S. Adults 2
... Philadelphia™ Collar and Stabilizer Plastazote® ... reinforcements. Hook-and-pile closure straps. Chin ... mandibular pieces may be interchanged ... easily to the standard Philadelphia ...
Urethrotome - non-optical...
Optical Urethrotome for Telescope 2.7 mm for children....
... The USA Elite ... Visual Urethrotomes are utilized ... strictures and bladder neck ... The visual obturator converts ...
Medicine Products: